Moderna more effective than Pfizer in direct comparison against the Delta variant

Posted on Aug 18, 2021

The Moderna vaccine outperformed Pfizer/BioNTech in protection against the Delta variant in an observational study released as a preprint this week.

The study compared effectiveness of the two vaccines over the period of January to July 2021, in which the Alpha and Delta were prevalent. 

Both vaccines’ effectiveness was reduced by the Delta variant but Pfizer/BioNTech had a more pronounced reduction. Moderna was 76% effective against infection with Delta in comparison to Pfizer/BioNTech’s 42% effectiveness. 

Furthermore, it found that Moderna conferred a two-fold risk reduction against breakthrough infection compared to Pfizer/BioNTech. Notably there was no difference in ICU admissions and no deaths recorded in the vaccinated population. 

For more information or if you have specific data requests, contact the team at

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022